Hepalink net profit rose sharply to 599 million yuan in first half

The highest price of the new shares issued by the Sea of Puri (002399) recently released the first semi-annual report. While overseas sales continued to grow strongly in the first half, domestic sales surged 6.7 times-fold. The first half of the total operating income of 1.809 billion yuan, net profit of 599 million yuan, year-on-year growth of 132%, 127%, earnings per share 1.6 yuan, net assets yield of 18.31%.　　The company expects January-September results to grow 90% to 120% from the same period last year. In the first half of the year, the results showed a notable increase from the same period in 2009, mainly due to the increase in product sales and sales prices. It is noteworthy that the company heparin sodium raw materials, the gross profit margin has declined, of which the FDA grade heparin sodium raw drug gross profit rate fell 6.56% to 44.76% year-on-year, the income reduction of 33.53% to 250 million yuan, operating costs decreased by 24.58%. At the same time, the company's ordinary grade product income rose 2.7 times times to 1.56 billion yuan, gross margin rose to 44.34%. Market conditions, foreign sales continue to show a strong growth trend, the year-on-year increase of 126%, reached 1.745 billion yuan, while domestic sales surged 6.7 times times, income of 63.7451 million yuan. In addition, because of the huge amount of funds raised, the company's money surged 11.7 times times to 5.663 billion yuan.　　At the same time, the company increased the procurement of raw materials, inventory increased by 119.67%. The company said that the second half will continue to strengthen product quality and safety production management, to ensure product quality stability and international leadership to meet the different needs of different customers.　　At the same time, to speed up the production of 5 trillion units per year and in line with the United States FDA certification and the European Union CEP certification standard of heparin sodium raw material drug expansion project construction work, at present the project construction is progressing smoothly. In addition, Hepalink will usher in the launch of the IPO on August 6, the lifting of the number of 8 million shares, in accordance with the 30th Hepalink closing price of 133.58 yuan, the lifting of the market value of nearly 1.07 billion yuan.　　In the end of June, the company ranked the top ten of the unlimited conditions of sale of shareholders, easy to reach its fund has six seats, total shareholding 3.67 million shares, big into the value Growth Fund holding 458,000 shares, natural Zhou Rong and sheep June Chen held 303,000 shares and 198,000 shares respectively. The reporter also learned from the relevant channels, USP (United States Pharmacopoeia Commission) president Dr. WILLIAMS6 has visited Hepalink to discuss with the company on the standard of heparin sodium in the United States Pharmacopoeia. According to people familiar with the analysis, USP's trip not only said that the company's heparin sodium raw materials have international competitiveness and has achieved a certain competitive advantage, but also means that hepalink in the international industry in the field of the leadership of the world's more recognized by authoritative organizations and attention.